ONCOLYTICS BIOTECH INC.

Analyst Reco. Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Delayed Toronto S.E. Other stock markets 09:50:29 2024-04-18 am EDT			5-day change	1st Jan Change
1.41 ^CAD	-2.08%		-11.32%	-21.23%

Apr. 11	Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	CI
Apr. 11	Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating	Nov. 13	MT
Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate"	23-06-05	MT
Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate	23-06-05	CI
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target	23-05-24	MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating	23-03-06	MT
Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting	22-11-07	CI
Oncolytics Biotech Brief: Reporting Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting	22-11-07	MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3	22-10-06	MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech	22-03-04	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech	21-03-12	MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target	21-02-17	MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3	20-11-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer